Index

Note: Page numbers in *italics* refer to Figures; those in **bold** to Tables

15-day alert reports, initial and follow-up  **149**, 153–5, 156
120-Day Safety Update Report  34, 73–4
2012 amendments, EU pharmacovigilance legislation 146

active ingredient  82, 128
ad-hoc safety reviews
  preparation and planning  172–3, 173
  requirements and scheduling  171–2
  template, generic model  173–9
adverse drug reactions (ADR)  68
  serious adverse reactions (SARs)  21–2
adverse events (AE)
  epidemiological data  88–9
  listed and unlisted  130, 142–3
  summary tabulation  45–6, 66, 133–4, 161–2
  see also serious adverse events; treatment-emergent adverse events
alternative therapies, comparison  112
animal studies data  71, 72
Annual Safety Report (ASR) compared with US IND Annual Report  5–6, 6, 8–9
data sources  8
requirement in Australia  188–9
scope and structure  6–7, 7
submission schedule  7
Australia and New Zealand, pharmacovigilance  188–9
Benefit-Risk Evaluation Report
  occasions and methods of preparation  76, 107–8, 108
  scope and general guidelines  106, 106
  summarized for Periodic Safety Update Reports  140
template, generic model
  benefit evaluation  109–12
  introductory layout  109
  risk evaluation  112–14
  summary (conclusions)  114
benefit-risk profile
  for clinical trial stage  28–9
  post-marketing, fine tuning  83
Biologic License Application (BLA) 60, 97
holder, post-marketing responsibilities 146, 171
breast-feeding and drug safety 56, 144–5

Canada, pharmacovigilance 188
case reports
presentation format (for PSUR) 133–7, 137
summary and analysis in ad-hoc safety reviews 176, 177
in PSUR Addendum 163
in Summary Bridging Report 169
in US PADER 152–6

Central Drugs Standards Control Organization (India) 189
chronic conditions, long-term treatment 51
clinical trials
data used for benefit-risk evaluation 111, 113
descriptive details (for DSUR) 19–20
excluded patient populations 85
long-term follow-up data 2–4
patient exposure details (for PSUR) 133, 168–70
reporting requirements
current practice 9–15
outside EU/US 186–7, 188, 189, 190
previous arrangements, United States and Europe 6–9
recent integration 1, 5–6
summary, in marketing application phase 41–5, 63–5
Clinical Trials Application (CTA) 7
Clinical Trials Directive 6–7
Code of Federal Regulations (CFR) 7, 60, 73, 147
combination therapies 24
Committee for Medicinal Products for Human Use (CHMP) 6
Common Technical Documentation (CTD) modules 2–3, 33, 60, 187
communication plans (for healthcare professionals) 98, 102
Company Core Safety Information (CCSI) 130–1, 155
company-sponsored clinical studies 136–7, 162
consumer reports 142
Council for International Organizations of Medical Sciences (CIOMS)
establishment and issue of guidelines 120
recommendations for benefit-risk evaluation 106
reports used in safety review and questions 173, 179, 183
working group for DSUR specifications 11
cumulative patient exposure 21, 110
data interpretation 50, 142
Data Lock Point (DLP) 12, 82
related to PSUR/PADER submission 118, 124, 150
data presentation, pooling 45, 60–1
data sources
Ad-Hoc Safety Review 172, 173
Benefit-Risk Evaluation Report 107, 108
Development Safety Update Report (DSUR) 6, 11, 13
EU Annual Safety Report (EU ASR) 8
EU Periodic Safety Update Report (EU PSUR) 120, 122, 123
EU Risk Management Plan (EU RMP) 78, 78
Integrated Summary of Safety (ISS) 60–1
Response to Questions
Document 179, 179
Risk Evaluation and Mitigation Strategies (REMS) Report 97, 99
Summary Bridging Report (SBR) 164
Summary of Clinical Safety (SCS) 35, 36, 42
US IND Annual Report 10
US Periodic Adverse Drug Experience Report (US PADER) 148, 149
Dear Healthcare Professional Letter (DHCPL) 102, 106
deaths, analysis of incidence 49–50
demographic characteristics, study population 43–5, 44, 64, 72
Development International Birth Date (DIBD) 11, 12
development phase, clinical see clinical trials
Development Safety Update Report (DSUR)
adoption outside EU/US 187, 188, 189
origins and scope 5–6, 9–11, 12
preparation and planning 11–13, 13, 14
template, generic model 15
appendices 30
comparisons and updates 26–8
context of clinical trial evaluation 17–21
heading format and introduction 15–17
safety data presentation 21–6
summary evaluation and conclusions 28–9
discontinuation of treatment 51, 57, 68–9
dose
in clinical development and in treatment 64–5
related to adverse events 47–8, 71
related to proposed indications 82
driving ability, effects of drugs 57–8
drug abuse 57, 89–90, 143
drug development, key stages 1–4, 2
drug interactions 55–6, 71
case report analysis 143–4
identified and potential risks 86–8, 88
Drug Safety Physician checking of data interpretation 50, 73, 183
review of line listing significance 125
selection of adverse events for analysis 55, 66, 69
DSUR see Development Safety Update Report
efficacy clinical trials findings 22–3, 23, 29
evidence of clinical benefit 111, 111
lack of, associated risks 26, 28, 139–40, 140
narrative description of assessment 42–3
related to dose 71
electronic document management 38, 125
Elements to Assure Safe Use (ETASU) 98, 100
implementation system 105
licensing categories 103–5
reasons for inclusion in risk assessment 102
epidemiological data 88, 108, 110
EU Annual Safety Report see Annual Safety Report (ASR)
EU Periodic Safety Update Report (EU PSUR) see Periodic Safety Update Report
EU Qualified Person for Pharmacovigilance (EUQPPV) 96
EU Risk Management Plan (EU RMP) see Risk Management Plan (RMP)
European Medicines Agency 77, 79, 119
European Union (EU) application procedures for marketing authorization 33–4, 75–6 clinical studies reporting, compared with US 5–6, 6, 8–9 Drug Regulating Authorities Clinical Trials (EudraCT) 20, 21 global adoption of pharmacovigilance practices 186 post-marketing pharmacovigilance, compared with US 118, 119 recent Directive amendments 146 see also Annual Safety Report; Periodic Safety Update Report; Risk Management Plan executive summaries (introductory) 17, 128–9, 174 exposure (of patients/subjects to drug) 20–1, 41 data presentation 161, 167–8 database limitations 84–5 estimate of amount, calculation 58, 132–3, 133 source data 43, 64–5 Food and Drug Administration (FDA) clinical trials reporting requirements 5, 6, 7–9 requests for risk evaluation 76, 97 safety reviews for marketing authorization 34, 60 submission requirements, periodic safety updates 118, 149 formulation, pharmaceutical 81 gastrointestinal disorders, analysis example 135–7, 136, 137 generic models see templates
Health Canada 188 Health Sciences Authority, Singapore 190–1 healthcare professionals (HCPs) certification, to ensure safe drug use 103 ‘Dear Doctor’ letters 102, 130, 156 illegal use (drug misuse) 57, 90, 144 incidence cut-off threshold 46–7, 67, 69 India, pharmacovigilance 189–2 infectious agents, potential transmission 90 injection site reactions (PADER example) 154, 154 Integrated Summary of Safety (ISS) compared with Summary of Clinical Safety 33–4, 60–1 template, generic model adverse events analysis 65–70 arrangement and level of detail 61 clinical development program background 63–5 drug dose and interactions 71–2 exposure and subject demographics 65 heading and introductory details 62–3 laboratory and non-clinical data 70–1 long-term and withdrawal effects 72–3 international birth date (IBD) 7, 11, 12, 121 International Conference on Harmonization (ICH) 76–7, 120 E2C line listings (for PSUR/ PADER) 122, 124, 132, 149 non-signatory countries 183–4, 188–91 investigational medicinal products (IMPs) clinical trials reports required 7 description, in report introductions 17
documentation outside EU/US 186–7, 188, 189, 190
patient exposure to 20–1
possible regulatory actions 18
Investigational New Drug (IND) Annual Report
compared with EU Annual Safety Report 5–6, 6, 8–9
data sources 10
scope and structure 8–9, 9
submission schedule 7, 9
Investigator’s Brochure (IB) 12, 19
Japan, pharmacovigilance
clinical trials medical writing 186–7
marketed products medical writing 187–8
regulatory governance 186
labeling, product 3, 34
avoidance of incorrect drug administration 94
comparison with post-marketing safety data 59
draft preparation and updating 37, 155
patient information elements required in US 101
presentation for ad-hoc safety review 178
laboratory investigations, presentation 53, 139
late-breaking information 122, 139–40
letters to healthcare professionals 102, 130, 156
license renewal 18, 76, 118, 157, 172
literature reviews, for safety data 25–6, 37, 70, 139
database searching 176
long-term treatment effects 51, 72–3, 145, 182–3, 183
machine operation, effects of drugs 57–8
marketed products
actual use data 85–6
cumulative patient exposure 21, 110
documentation outside EU/US 187, 188, 189, 190–1
mandatory periodic documents 3–4, 117–19
names, codes and characterization 81–2
pharmacological class, attached risks 88–9
review of safety information and findings 25, 58–9, 59, 113
marketing authorization conditions for license continuation 120
documentation required 2–3, 33–4, 75–6, 172
records of dates and places 82, 129
status of products in clinical studies 17–18
Marketing Authorization Application (MAA) 33, 75
Marketing Authorization Holder (MAH) 3
pharmacovigilance monitoring responsibilities 117, 118, 119, 171
proactive initiation of risk assessments and studies 75, 76, 129, 156
statement on benefit-risk profile 114
Medical Dictionary for Regulatory Activities (MedDRA) 161, 137, 161, 176
medication errors, likelihood and effects 94, 139, 143–4, 144
medication guides (for patients) 97, 101
MedWatch forms 149, 156, 173, 179
mental impairment effects 57–8
milestone records, in action planning 93, 100
Ministry for Health, Labor and Welfare (MHLW), Japan 186, 186
models, generic see templates
monitoring
of marketed products, duration and need for 117
of specific safety concerns 120, 171–2
multiple drug treatment 24
narrative descriptions
of clinical safety studies 42–3, 52
individual case histories 50, 134–5, 161
nervous system disorders, ad-hoc safety review example 175–8, 177
New Drug Application (NDA) 33, 60, 75, 105
holder, post-marketing responsibilities 145, 171
New Zealand, pharmacovigilance 188–9
off-label (unapproved) use, potential risks 90, 139
organ systems, as basis for adverse event analysis 52
overdose data analysis 56–7, 89, 144, 144
package inserts
as information for patients 98, 101
US, for healthcare professionals 34, 156
paediatric drug use 85, 90, 131
accidental 94
patients
controlled access to treatment 104–5
populations excluded from clinical studies 85
special groups and safety analysis 54–5, 69, 145
Periodic Adverse Drug Experience Report (PADER)
compared with EU Periodic Safety Update Report 118, 119
general principles and guidelines 146–7, 148
planning and preparation 148–50, 149, 149, 150
template, generic model
alert reports analysis 153–5
contents and scope
summary 152–4
line listings and forms appended 156
narrative discussion of actions 155–6
Periodic Safety Update Report (PSUR) 7
2012 amendments 146
and ad-hoc safety reviews 174
Addendum Report 118, 157–63
compared with US Periodic Adverse Drug Experience Report 118, 119
guidelines and scope 119–20, 121
implementation outside EU 187, 188, 189, 190, 193
planning and preparation 120, 122, 123, 123–6, 124
reviewed in Summary Bridging Report 164, 164
scheduling, and revision circumstances 120, 121
template, generic model
contents, summary and introduction 127–9
individual case histories 132–6
marketing authorization and reference safety status 129–32
patient exposure 131–2
reports and study information 137–41
safety evaluation and conclusions 141–6
pharmacokinetic/dynamic (PK/PD) studies 55, 72, 180, 182
pharmacovigilance documentation, key stages 1–4, 2
**Pharmacovigilance Plan (as part of RMP)** 77, 90–3

physical examinations, data presentation 53–4

planning timescales see timelines

pooling (of data) 45, 60–1

post-marketing lifetime see marketed products

preferred terms (PT), for database search 176

pregnancy and lactation, drug safety analysis 56, 144–5

**PSUR** see Periodic Safety Update Report

PSUR Addendum Report preparation and submission 118, 157
template, generic model 158–63

published studies see literature reviews, for safety data

quality, batch variation 138, 180

Quality Control (QC), role in document review 37, 39, 125

questions, regulatory authority see Response to Questions Document

Reference Safety Information (RSI) during clinical studies 19, 21

marketed products, official summary and updating 121, 130–1, 155, 160, 167

region-specific information 13, 26–7, 27, 30, 187

registry enrolment, patients 104–5, 145

regulatory authorities (RA) actions during clinical trials, possible 18

opinions on risk minimization 76

PSUR review, and Summary Bridging Reports 164

questions and clarification requests 172

requests for additional safety reviews 171–2

review of marketing application dossiers 33

in specific global regions

Australia New Zealand Therapeutic Products Authority 188–9

Health Canada 188

India, Central Drugs Standards Control Organization 189

Japan, Ministry for Health, Labor and Welfare (MHLW) 186

Singapore, Health Sciences Authority 190–1

Taiwan Department of Health 190

UK, Medicines and Healthcare products Regulatory Agency (MHRA) 175

summary of actions taken 86, 129–30, 155, 160, 167

regulatory guidelines and general principles

Benefit-Risk Evaluation Report 106, 106

Development Safety Update Report (DSUR) 9–11, 12

EU Periodic Safety Update Report (EU PSUR) 119–20, 121

EU Risk Management Plan (EU RMP) 76–7, 77

Integrated Summary of Safety (ISS) 60

Risk Evaluation and Mitigation Strategies (REMS) Report 96–7, 98

Summary of Clinical Safety (SCS) 34–5, 35


Response to Questions Document preparation and planning 179, 179–80

requirements from regulators 172

template, generic model 180–4
Index

review teams
Ad-Hoc Safety Review 172
Benefit-Risk Evaluation Report 107
Development Safety Update Report (DSUR) 11, 14
EU Periodic Safety Update Report (EU PSUR) 123, 123
EU Risk Management Plan (EU RMP) 78, 79
Integrated Summary of Safety (ISS) 61
Response to Questions Document 179–80
Summary of Clinical Safety (SCS) 35–6, 37
US Periodic Adverse Drug Experience Report (US PADER) 146, 147
Risk Evaluation and Mitigation Strategies (REMS) Report

data and time planning 97–8, 99
occasions for preparation 76, 97
origins and scope 96–7, 98
template, generic model
elements of report 100–6
statement of goals 99–100

risk management
activity planning and follow-up 75–6, 90–2
changes and regulatory actions 18, 86
evaluation, for benefit-risk assessment 112–14
identification and evaluation, clinical trials 28–9
minimization
evaluation of needs 93–4
Risk Minimization Plan (RiskMAP) 95
unknown and potential risks 86–90
Risk Management Plan (RMP)
clinical trials basis for safety specification 29
planning and preparation 77–9, 78, 79, 79
scope and purpose 75–6, 77
summary of updates, in PSUR 140
template, generic model
format recommended, source and layout 79–81
Pharmacovigilance Plan 90–3
product information details 81–2
risk minimization actions 93–5
Safety Specification 83–90
summary and responsible contacts 95–6

safety
assessment, summary and evaluation 28–9, 33–4
evaluation plan description (for SCS) 41–2
in periodic update reports 145–6, 163, 169
clinical trials findings 22–3, 23, 112–13
concerns and specification of actions 30, 83, 91–2
ad-hoc safety reviews 171–2, 175–8
new and potential identified risks 86, 87
targeted study data 138
documentation, key stages 1–4, 2
non-clinical data and study programmes 24, 25, 84
routine post-marketing surveillance 91, 117–18
see also risk management
Safety Specification (in Risk Management Plan) 77, 83–90
Schedule Y, Drugs and Cosmetics Act (India) 189, 190
scheduling (submission frequency)
Benefit-Risk Evaluation Report 107
Development Safety Update Report (DSUR) 11
EU Periodic Safety Update Report (EU PSUR) 120, 121
Index 267

EU Risk Management Plan (EU RMP) 77
Risk Evaluation and Mitigation Strategies (REMS) Report 97, 105–6
US Periodic Adverse Drug Experience Report (US PADER) 148, 149
serious adverse events (SAEs)
in company’s safety database 176
narrative description and analysis 134–6, 155
tabulated summaries
for Development Safety Update Report 22
for Integrated Summary of Safety 67–8
for Summary of Clinical Safety 50–1
serious adverse reactions (SARs) 21–2
severity of adverse effects 48–9, 67
side effects, detection of 117
Singapore and Taiwan,
pharmacovigilance 190–1
source data see data sources
stakeholder approval see review teams
standardized MedDRA Queries (SMQ) 176
statistical analysis, safety data (ISS) 34, 61
study protocols (risk management) 92
submission frequency see scheduling
Summary Bridging Report (SBR) preparation and submission 118, 164
template, generic model 164–9
Summary of Clinical Efficacy (SCE) 42–3
Summary of Clinical Safety (SCS) compared with Integrated Summary of Safety 33–4, 60
preparation and planning 35–9, 36, 37, 38
scope and guidelines 34–5, 35, 187
template, generic model adverse events analysis 45–52
drug exposure, subjects and studies 41–5
heading and introductory details 39–41
individual and extrinsic factor effects 54–8
laboratory and vital sign assessments 53–4
post-marketing and reference data 58–60, 59
Summary of Product Characteristics (SmPC) 34, 86, 114
surveillance see monitoring
syndromes, as basis for adverse event analysis 52
System Organ Class (SOC) analysis of post-marketing adverse events 59, 134–5, 141–2, 153
clinical development program TEAE analysis 66, 67, 67
Taiwan, pharmacovigilance 190–1
templates
Ad-Hoc Safety Review 173–9
Benefit-Risk Evaluation Report 109–14
Development Safety Update Report (DSUR) 15–30
EU Periodic Safety Update Report (EU PSUR) 126–46
EU Risk Management Plan (RMP) 80–96
Integrated Summary of Safety (ISS) 61–73
PSUR Addendum Report 159–64
Response to Questions Document 180–4
Risk Evaluation and Mitigations Strategies (REMS) Report 99–106
Summary Bridging Report (SBR) 166–70
Index

templates (Continued)
  Summary of Clinical Safety (SCS) 39–60
  US Periodic Adverse Drug Experience Report (US PADER) 151–6
time-to-onset (TTO), in case study reporting 137, 177
timelines (for report preparation)
  Ad-Hoc Safety Review 172–3
  Benefit-Risk Evaluation Report 107–8
  Development Safety Update Report (DSUR) 11–13, 14, 15
  EU Periodic Safety Update Report (EU PSUR) 124, 124–5
  EU Risk Management Plan (EU RMP) 78–9, 79
  Integrated Summary of Safety (ISS) 61
  Response to Questions Document 180
  Risk Evaluation and Mitigation Strategies (REMS) Report 98
  Summary of Clinical Safety (SCS) 36–9, 38
  US Periodic Adverse Drug Experience Report (US PADER) 150, 150
toxicity, risk reporting 84
transmission of infectious agents 90
treatment-emergent adverse events (TEAEs), clinical studies
  assessment of rates 34, 49
  criteria of significance 51
  data recording and presentation 45–6, 46, 47, 66
  definition 35, 45
  incidence analysis 46–52, 48, 50, 66–70, 68
  treatment purpose description 110–11
  United States (US)
  application procedures for marketing authorization 33–4, 60
clinical studies reporting, compared with EU 5–6, 6, 8–9
post-marketing pharmacovigilance, compared with EU 118, 119
risk management measures 76
legal status of risk assessment targets 100
RiskMAP Minimization Plan and its replacement 96–7
see also Food and Drug Administration; Investigational New Drug Annual Report; Periodic Adverse Drug Experience Report; Risk Evaluation and Mitigation Strategies Report
  United States Package Insert (USPI) 34, 155
  updating
    presentation of new RMP data 92–3
    reasons for 3–4
    regular, for risk evaluation and management 75–6
    scheduled and additional requirements 118
  US, 120-day Safety Update Report 34, 73–4
see also Development Safety Update Report; Periodic Safety Update Report
  Uppsala Monitoring Centre–Africa 186
US IND Annual Report see
  Investigational New Drug (IND) Annual Report
US PADER, for marketed products see
  Periodic Adverse Drug Experience Report
  Vaccine Adverse Event Reporting System (VAERS) 156
vital signs, data presentation 53–4
withdrawal effects, data and analysis 57, 73
worldwide marketing authorization (WWMA)
appended to ad-hoc safety reviews 175

status information (for DSUR) 17–18
updated status (for periodic safety updates) 128–9, 159–60, 166